UniProtKB/SwissProt variant VAR

Variant information

Variant position:

385

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

Disease [Disclaimer]

The variants are classified into three categories: Disease, Polymorphism and Unclassified.

Disease: Variants implicated in disease according to literature reports.
Polymorphism: Variants not reported to be implicated in disease.
Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:

From Asparagine (N) to Aspartate (D) at position 385 (N385D, p.Asn385Asp).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from medium size and polar (N) to medium size and acidic (D)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

1

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Involvement in disease:

Waardenburg syndrome 2A (WS2A) [MIM:193510]: WS2 is a genetically heterogeneous, autosomal dominant disorder characterized by sensorineural deafness, pigmentary disturbances, and absence of dystopia canthorum. The frequency of deafness is higher in WS2 than in WS1. {ECO:0000269|PubMed:28236341, ECO:0000269|PubMed:8589691}. Note=The disease is caused by mutations affecting the gene represented in this entry.

The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:

In WS2A.

Any additional useful information about the variant.

Sequence information

Variant position:

385

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

526

The length of the canonical sequence.

Location on the sequence:

QREQQRAKELENRQKKLEHA N RHLLLRIQELEMQARAHGLS

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QREQQRAKELENRQKKLEHANRHLLLRIQELEMQARAHGLS

Mouse                         QREQQRAKDLENRQKKLEHANRHLLLRVQELEMQARAHGLS

Rat                           QREQQRAKDLENRQKKLEHANRHLLLRVQELEMQARAHGLS

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 526	Microphthalmia-associated transcription factor
Region	374 – 395	Leucine-zipper
Coiled coil	355 – 402
Modified residue	405 – 405	Phosphoserine; by GSK3
Mutagenesis	405 – 405	S -> AP. Loss of phosphorylation and function.
Helix	357 – 401

Literature citations

The mutational spectrum in Waardenburg syndrome.
Tassabehji M.; Newton V.E.; Liu X.-Z.; Brady A.; Donnai D.; Krajewska-Walasek M.; Murday V.; Norman A.; Obersztyn E.; Reardon W.; Rice J.C.; Trembath R.; Wieacker P.; Whiteford M.; Winter R.; Read A.P.;
Hum. Mol. Genet. 4:2131-2137(1995)
Cited for: VARIANTS WS2A LYS-310; ARG-324 DEL; PRO-357; ASP-385 AND PRO-405;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O75030: Variant p.Asn385Asp